JBM Research offers innovative bespoke research tailored to your product’s needs.
Whether working with the existing evidence-base, through meta-analysis or disease modelling, or conducting original research in epidemiology, clinical effectiveness or healthcare delivery, JBM Research creates a platform for growth into new or established markets. We have extensive experience in this field and can advise as to which approach is best supported by available data or readily accessible by conducting specific elements of original research.
Meta-analysis
In cases where evidence is available from multiple studies, making a therapeutic choice can be a complex decision. In such situations meta-analysis can clarify the product selection process for the clinician. By using Cochrane Collaboration-approved methodology, we are able to develop meta-analytical support materials with an exceptional degree of impact and credibility. In addition to providing compelling support for promotional messaging, meta-analysis has the potential to support regulatory changes without a requirement to conduct new randomised control trials.
Pearse RM, Belsey JD, Cole JN et al. Effect of dopexamine infusion on mortality following major surgery: Individual patient data meta-regression analysis of published clinical trials. Crit Care Med 2008;36:1323-1329. PubMed abstract.
Disease modelling
Disease modelling supports product use in a disease area which suffers from a limited perception of need amongst physicians and purchasers. Applying the principles of product marketing to the disease itself, JBM Research has demonstrated success in supporting a national re-prioritisation of resources to therapy areas that previously received little clinical attention or funding. By using disease modelling we are able to generate precise quantification of patient populations and inform your strategic marketing planning throughout the product life-cycle.
We also produce financial impact models intended for use by representatives and NHS Liaison Divisions. Through focusing on intuitive analyses our financial impact models simplify health economic discussions and so enable your sales force to convey clear economic messages without the need for additional specialist training.
Belsey J, De lusignan S, Van Vlymen J et al. Reducing coronary risk by raising HDL-cholesterol: Risk modelling the addition of nicotinic acid to existing therapy. Curr Med Res Opin 2008;24:2703-2709. PubMed abstract.
Original research
Original research can complete gaps in the product evidence-base or disease literature. We offer a complete project management capability from identification of investigators to manuscript preparation and publication in peer-reviewed journals.
Clinical effectiveness analyses can illustrate how your product performs in real-life clinical practice and provide support for comparative efficacy or tolerability messaging from a post-marketing setting.
Healthcare delivery programmes can establish examples of effective service infrastructure development to ensure that mechanisms are in place to implement your product’s evidence-base and drive sales.
Our epidemiological research has successfully provided a platform for product growth in disease areas lacking adequate published data, in order to persuade physicians and service commissioners to address an unmet medical need.
Amiel SA, Dixon T, Mann R et al. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-254. PubMed abstract.
